Physician profile
Sonal Sethi
NPI 1437348281
$4,371.86
in general payments reported to CMS, 2019-2025
47 companies · $931 in 2025
The $931 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70.58 · 2020: $26.61 · 2021: $11.92 · 2022: $559 · 2023: $1,804 · 2024: $969 · 2025: $931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,586 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,585.87 |
| Education | $118.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $430.46 | 2022-2025 | |
| Celgene Corporation | $349.53 | 2022-2024 | Reblozyl, Pomalyst, Opdualag |
| Merck Sharp & Dohme LLC | $309.71 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $253.98 | 2022-2025 | Imbruvica, Rybrevant, Carvykti |
| Genzyme Corporation | $251.49 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $226.79 | 2023-2025 | Calquence, Imfinzi |
| Pharmaessentia USA Corporation | $220.19 | 2022-2025 | Besremi |
| E.R. Squibb & Sons, L.L.C. | $205.91 | 2022-2025 | Opdualag, Opdivo |
| Pfizer INC. | $202.66 | 2019-2025 | |
| Amgen INC. | $161.35 | 2022-2023 | Vectibix, Xgeva, Nplate |
| Astellas Pharma US INC | $143.09 | 2019-2025 | Xtandi, Padcev |
| Puma Biotechnology, INC. | $138.40 | 2023-2025 | Nerlynx |
| Gilead Sciences, INC. | $123.24 | 2021-2024 | |
| Karyopharm Therapeutics INC. | $98.47 | 2023-2025 | Xpovio |
| Kite Pharma, INC. | $85.24 | 2022-2025 | Yescarta |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $79.18 | 2024-2025 | Ojjaara |
| Deciphera Pharmaceuticals INC. | $78.29 | 2023-2025 | Qinlock, Romvimza |
| Jazz Pharmaceuticals INC. | $67.78 | 2022-2024 | |
| Beigene USA, INC. | $65.59 | 2023-2024 | Brukinsa |
| Takeda Pharmaceuticals U.S.A., INC. | $56.55 | 2022-2023 | Ninlaro |
| Aveo Pharmaceuticals, INC. | $54.21 | 2022-2023 | Fotivda |
| Exelixis INC. | $54.07 | 2023-2024 | Cabometyx |
| Daiichi Sankyo INC. | $54.00 | 2024 | Enhertu |
| Beone Medicines USA, INC. | $48.38 | 2025 | Tevimbra, Brukinsa |
| Adaptive Biotechnologies Corporation | $47.95 | 2023-2024 | Clonoseq |
| Eisai INC. | $41.42 | 2023 | |
| Rigel Pharmaceuticals, INC. | $34.29 | 2024 | Rezlidhia, Tavalisse |
| Array Biopharma INC | $32.91 | 2024 | Braftovi, Mektovi, Lorbrena |
| Emd Serono, INC. | $31.56 | 2024 | |
| Genentech USA, INC. | $31.56 | 2024 | Itovebi |
| Pharmacosmos Therapeutics INC. | $31.36 | 2023 | Monoferric |
| Blueprint Medicines Corporation | $30.25 | 2023 | Ayvakit |
| Boston Scientific Corporation | $27.72 | 2023 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Mirati Therapeutics, INC. | $26.41 | 2023 | Krazati |
| Regeneron Healthcare Solutions, INC. | $25.33 | 2024 | Libtayo |
| Springworks Therapeutics, INC. | $25.18 | 2025 | Gomekli |
| Cti Biopharma Corp. | $24.79 | 2023 | Vonjo |
| Stemline Therapeutics INC. | $24.71 | 2023 | Orserdu |
| Tersera Therapeutics LLC | $24.36 | 2022 | |
| Azurity Pharmaceuticals, INC. | $22.95 | 2025 | Danziten |
| Abbvie INC. | $22.26 | 2024 | |
| Tempus Ai, INC | $21.08 | 2024 | Xt Cdx |
| Seagen INC. | $19.63 | 2023 | Adcetris |
| Agios Pharmaceuticals, INC. | $19.36 | 2025 | Pyrukynd |
| Helsinn Therapeutics (U.S.), INC. | $18.11 | 2023 | Akynzeo |
| Incyte Corporation | $17.27 | 2025 | Monjuvi |
| Tactile Systems Technology INC | $12.84 | 2023 | Entre Plus, Flexitouch Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonal Sethi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.